Abstract 3007: Dyslipidemia Burden in Patients With Peripheral Arterial Disease
Background: PAD affects approximately 8 million people in the US, and is established as a CHD risk equivalent. However, only 25% of PAD patients ≥65 years old are receiving treatment. Full characterization of modifiable risk factors in patients with PAD, such as dyslipidemia, will be an important step in the development and assessment of effective prevention strategies.
Methods: Patients were selected from a 2.1 million record managed care plan database if they had a baseline lipid panel between 1/1/00–12/31/01, no concomitant lipid pharmacotherapy, and continuous plan eligibility for 24 months; and were retained for this analysis if they had a diagnosis or procedure establishing the presence of PAD. Descriptive analyses of lipid values, optimal values achieved, and treatment patterns at baseline, and over 3-years of follow-up were conducted.
Results: The study sample was 2,568 patients; mean age 70±12 years; male 52%, hypertension 68%; diabetes 19%. Non-optimal LDL-C with non-optimal HDL-C, and/or TG was present in 42% at baseline and 33% at year 3; and isolated high LDL-C was observed in 37% at baseline and 33% at year 3. At baseline, 45% of men had HDL-C <40mg/dL, and 41% of women had HDL-C <50 mg/dL. Dyslipidemia therapy was initiated in 34% of patients after a mean delay of 8±10 months, with statin monotherapy accounting for 80% of therapy and combination therapy 13% (4% of total).
Conclusions: There is a significant, under-treated burden of dyslipidemia in patients with PAD, particularly elevated LDL-C concomitant with low HDL-C and/or high TG. Targeted prevention strategies should include lifestyle and pharmacologic interventions directed at modifying the entire lipid panel.